New drug duo tested to fight Tough-to-Treat lung cancer
Disease control
Completed
This study tested whether adding a new drug called bemcentinib (BGB324) to an existing immunotherapy (pembrolizumab) could help control advanced lung cancer that had worsened after prior treatment. It involved 99 adults with a specific type of lung cancer (adenocarcinoma) whose d…
Phase: PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC